pSivida to present at two US investor conferences

pSivida (ASX:PVA) will this week present details of the company at two US-based investment conferences.

The company will give a presentation at the Rodman & Renshaw Annual Global Investment Conference.

The presentation will take place at the Millennium Broadway Hotel in New York at 12.05 pm EDT on Tuesday (2.05 am AEST on Wednesday). It will be webcast here.

pSivida will also present at the Stifel Nicolaus Healthcare Conference at the Four Seasons Boston Hotel on Thursday at 11.30 am EDT (1.30 am AEST on Friday). It will also be webcast.

US-headquartered pSivida has been making progress with its strategy of developing its own sustained-delivery treatments for back-of-the-eye diseases, while also licensing its underlying drug delivery technology to other companies.

Alimera Sciences, which is licensing a pSivida ocular insert for diabetic macular edema (DME) treatment Iluvien, has secured approval in the UK, Austria, Portugal, France, Spain and Germany.

Iluvien launched in the UK in May, and the US FDA will decide by next month whether to approve the treatment in the US.

In April, pSivida also revealed that another pharmaceutical company had started evaluating using its ophthalmic drug delivery technologies.

pSivida (ASX:PVA) shares were trading 3.54% higher at $4.10 as of around 12.30 pm on Monday.